Vitamin D analog shuts down pancreatic cancer’s shield in clinical trial - new research from @danafarber.bsky.social’s and @salkinstitute.bsky.social published in @natcancer.nature.com. Read more: bit.ly/4fbfHlc
A small clinical trial led by Dana-Farber Cancer Institute researchers put a Salk Institute idea to the test in patients: that activating the vitamin D receptor can help reshape the protective environment surrounding pancreatic tumors in ways that could make the notoriously difficult-to-treat cancer more vulnerable to therapeutic treatments.
